Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche announced the EC has approved Actemra®/RoActemra® (tocilizumab) for treatment of giant cell arteritis, a chronic and potentially life-threatening autoimmune condition. Actemra/RoActemra is the first therapy approved for the treatment of GCA in Europe. September 22, 2017